Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scynexis Inc (NQ: SCYX )

2.275 -0.025 (-1.09%)
Streaming Delayed Price Updated: 3:19 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Scynexis Inc

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
SCYNEXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating SCYNEXIS, Inc. on Behalf of Scynexis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Scynexis Inc. (NASDAQ: SCYX) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
The Law Offices of Frank R. Cruz Continues Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens
Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted... 
Via Newsfile
SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections
SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions 
Via Spotlight Growth
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.